Pptn — predicted protein targets

Known targets — ChEMBL curated mechanism

ABL1 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB2 AGTR1 BCL2 BCL2A1 BCL2L1 BCL2L10 BCL2L2 BCR BRAF CHRM1 CHRNA10 CHRNA9 DRD1 DRD2 DRD3 DRD4 DRD5 EGFR F2 FLT1 FLT4 GCK GHSR GNRHR GRIN1 GRIN2A GRIN2B GRIN2C GRIN2D GRIN3A GRIN3B HTR1A HTR1B HTR1D HTR2A HTR2C HTR3A IDH2 KDR KIT MAOB MCL1 MTTP P P4HB PDGFRB PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 PIK3R5 PIKFYVE ROCK1 ROCK2 SLC18A2 SLC6A2 SLC6A3 SLC6A4 TACR1 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 gyrA gyrB parC parE pol

The experimentally established mechanism targets of Pptn. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	DRD5 known ✓	P21918	4/20	0.89

▸	DRD3 known ✓	P35462	3/20	0.89

▸	DRD1 known ✓	P21728	3/20	0.89

▸	HTR1A known ✓	P08908	2/20	0.89

▸	SLC6A2 known ✓	P23975	2/20	0.89

▸	AGTR1 known ✓	P30556	2/20	0.89

▸	SLC6A3 known ✓	Q01959	2/20	0.89

▸	ADRA2C known ✓	P18825	2/20	0.89

▸	ADRA2A known ✓	P08913	2/20	0.89

▸	ADRA1B known ✓	P35368	2/20	0.89

▸	EGFR known ✓	P00533	1/20	0.89

▸	ADRA2B known ✓	P18089	1/20	0.89

▸	SLC6A4 known ✓	P31645	1/20	0.89

▸	SLC18A2 known ✓	Q05940	1/20	0.89

▸	HTR1B known ✓	P28222	2/20	0.88

▸	HTR1D known ✓	P28221	2/20	0.88

▸	ADRB2 known ✓	P07550	1/20	0.88

▸	HTR2A known ✓	P28223	1/20	0.83

▸	ADRA1A known ✓	P35348	1/20	0.69

▸	P2RY14	Q15391	19/20	0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Pptn SCHEMBL13057620	0.94	P2RY14 (1.00)	P2RY14TMEM97DRD5DRD3ADRB3
Pptn SCHEMBL31722460	0.93	P2RY14 (1.00)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL30608323	0.91	P2RY14 (1.00)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL30608308	0.89	P2RY14 (1.00)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL2932404	0.88	P2RY14 (0.69)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL26033092	0.88	P2RY14 (0.83)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL2934980	0.88	P2RY14 (0.74)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL22996061	0.87	P2RY14 (0.79)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL30608298	0.85	P2RY14 (1.00)	P2RY14TMEM97DRD5DRD3ADRB3
SCHEMBL30608305	0.85	P2RY14 (1.00)	P2RY14TMEM97DRD5DRD3ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20100298347-A1	SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY	MERCK FROSST CANADA LTD (CA)	2010-11-25	—	—	US	disclosed
EP-2229373-A1	SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY	Merck Frosst Canada Ltd. (CA)	2010-09-22	—	—	EP	disclosed
WO-2009070873-A1	SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY	MERCK FROSST CANADA LTD. (CA)	2009-06-11	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100298347-A1	SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY	GPR119, GPR52, GPR35	DRD5 1185/4885DRD3 3705/4885DRD1 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.